copetohen

Copetohen is a synthetic opioid analgesic that was developed in the 1960s. It is a prodrug, meaning it is inactive until metabolized in the body. Copetohen is converted into its active metabolite, copetamide, which is a potent mu-opioid receptor agonist. Copetamide is responsible for the analgesic and sedative effects of copetohen.

The drug was marketed under the brand name Robichem. It was initially developed for use as a pre-operative analgesic, but its use was later discontinued due to concerns about its potential for abuse and dependence. Copetohen was also associated with several cases of fatal overdose, highlighting its high potency and risk of misuse.

Copetohen's mechanism of action involves binding to mu-opioid receptors in the brain, which are involved in the perception of pain. This binding leads to the release of endorphins, the body's natural painkillers, and the suppression of pain signals.

The drug was available in tablet form and was typically taken orally. Its onset of action was relatively rapid, with effects usually felt within 15-30 minutes. The duration of action was also short, typically lasting for 2-4 hours.

Copetohen's development was halted due to its potential for misuse and the associated risks. Its use is now restricted or prohibited in many jurisdictions due to these concerns. However, it remains of historical interest in the study of opioid analgesics and their potential risks.